Supposed “Junk” DNA, found in between genes, plays a role in suppressing cancer, according to new research by the Universities of Bath and Cambridge.
Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.
In a paper (“Transcriptional silencing of long noncoding RNA GNG12-AS1 uncouples its transcriptional and product-related functions”) that appeared February 2 in Nature Communications, the researchers explained that they used multiple small interfering RNAs (siRNAs) to silence GNG12-AS1, which is a long noncoding RNA (lncRNA). GNG12-AS1 is transcribed in an antisense orientation to a neighboring gene, the tumor-suppressor DIRAS3, downregulated in 70% of breast and ovarian cancer.
“While most siRNAs silence GNG12-AS1 post-transcriptionally, siRNA complementary to exon 1 of GNG12-AS1 suppresses its transcription by recruiting Argonaute 2 and inhibiting RNA polymerase II binding,” wrote the authors. “Transcriptional, but not post-transcriptional, silencing of GNG12-AS1 causes concomitant upregulation of DIRAS3, indicating a function in transcriptional interference.”
The authors noted that the transcriptional effect, the change in DIRAS3 expression, sufficed to impair cell cycle progression. In addition, the post-transcriptional impact, the reduction in GNG12-AS1 transcripts, altered MET signaling, effectively suppressing a gene network that prepares cells to change their shape and participate in metastasis.
Notably, the changes in signaling and metastatic behavior associated with the post-transcriptional effect were independent of the changes related to transcriptional interference. The last modifications affected both migratory behavior and the cell cycle.
“The cells in our body occur in numbers balanced by the level at which the new cells replace the old cells that die. Sometimes the switches that control this growth get stuck in the ‘on’ position, which can lead to cancer,” explained Dr. Murrell. “As the tumor grows and the cancer cells get crowded, they start to break away from the tumor, change shape, and can burrow through tissues to the bloodstream where they migrate to other parts of the body, which is how cancer spreads. This process is called metastasis and requires a whole network of genes to regulate the transformation of cell shape and mobilization.”
Low-Asparagine Diet Could Slow Breast Cancer's Spread
Triple-Negative Breast Cancer Cell Growth May Be Driven by Tumor "Suppressor"
Novel Approach Shows Which Breast Cancer Patients May Develop Incurable Metastases
“In our study, we’ve identified that GNG12-AS1, a strand of noncoding RNA, prevents the growth switch from getting stuck and suppresses metastasis,” Dr. Murrell continued. “The specific genomic region where this noncoding RNA is located often gets damaged in breast cancer patients—this control is removed, and the cancer cells spread.”
“Research like this is helping to unpick the precise details about how [noncoding genome] regions work,” added Kat Arney, Ph.D., science communication manager at Cancer Research UK. “[It sheds] light on their potential role in the development of cancer and pointing towards new approaches for tackling the disease.”
“Altogether,” concluded the authors of the Nature Communications paper, “our results demonstrate that a siRNA-based strategy can be employed to successfully separate functions that are due to lncRNA transcription from those of the transcript.”